Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,116
  • Shares Outstanding, K 16,871
  • Annual Sales, $ 150 K
  • Annual Income, $ -15,000 K
  • 60-Month Beta 1.70
  • Price/Sales 259.46
  • Price/Cash Flow N/A
  • Price/Book 2.81
Trade BCDA with:

Options Overview Details

View History
  • Implied Volatility 115.91%
  • Historical Volatility 48.72%
  • IV Percentile 71%
  • IV Rank 27.65%
  • IV High 299.02% on 03/16/21
  • IV Low 45.92% on 05/19/21
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 677
  • Open Int (30-Day) 495

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +624,475.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +7.32%
on 11/24/21
2.95 -25.42%
on 10/29/21
-0.51 (-18.82%)
since 10/26/21
3-Month
2.05 +7.32%
on 11/24/21
3.96 -44.44%
on 09/22/21
-0.75 (-25.42%)
since 08/26/21
52-Week
2.05 +7.32%
on 11/24/21
8.60 -74.42%
on 12/15/20
-0.17 (-7.17%)
since 11/25/20

Most Recent Stories

More News
BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.20 (-1.35%)
BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived...

BCDA : 2.20 (-1.35%)
Will BioCardia, Inc. (BCDA) Report Negative Q3 Earnings? What You Should Know

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BCDA : 2.20 (-1.35%)
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived...

BCDA : 2.20 (-1.35%)
BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived...

BCDA : 2.20 (-1.35%)
CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular...

BCDA : 2.20 (-1.35%)
BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)

SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc.  (Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright...

BCDA : 2.20 (-1.35%)
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be...

XXII : 2.60 (-6.47%)
ACOG.VN : 1.050 (-5.41%)
AYRO : 2.31 (-1.28%)
BCDA : 2.20 (-1.35%)
BLGO : 0.2099 (+4.95%)
BITF : 7.14 (-9.04%)
BITF.VN : 9.140 (-11.00%)
BAMM.CN : 0.440 (-3.30%)
BMMJ : 0.3480 (-7.22%)
BCTX : 10.20 (-0.10%)
BCTXW : 5.10 (-1.92%)
BCT.VN : 13.050 (-1.88%)
BioCardia to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ® , Inc.  (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 2.20 (-1.35%)
BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights

SAN CARLOS, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 2.20 (-1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.47
1st Resistance Point 2.34
Last Price 2.20
1st Support Level 2.10
2nd Support Level 2.00
3rd Support Level 1.86

See More

52-Week High 8.60
Fibonacci 61.8% 6.10
Fibonacci 50% 5.33
Fibonacci 38.2% 4.55
Last Price 2.20
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar